SG1893G - Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations - Google Patents

Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations

Info

Publication number
SG1893G
SG1893G SG18/93A SG1893A SG1893G SG 1893 G SG1893 G SG 1893G SG 18/93 A SG18/93 A SG 18/93A SG 1893 A SG1893 A SG 1893A SG 1893 G SG1893 G SG 1893G
Authority
SG
Singapore
Prior art keywords
preparation
biologically active
pharmaceutical preparations
active fragments
antihemophilic factor
Prior art date
Application number
SG18/93A
Other languages
English (en)
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20359353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG1893(G) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of SG1893G publication Critical patent/SG1893G/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D31/00—Protective arrangements for foundations or foundation structures; Ground foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Structural Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Environmental & Geological Engineering (AREA)
  • Hydrology & Water Resources (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Paleontology (AREA)
  • Civil Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG18/93A 1985-03-05 1993-01-05 Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations SG1893G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof

Publications (1)

Publication Number Publication Date
SG1893G true SG1893G (en) 1993-06-11

Family

ID=20359353

Family Applications (1)

Application Number Title Priority Date Filing Date
SG18/93A SG1893G (en) 1985-03-05 1993-01-05 Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations

Country Status (10)

Country Link
US (2) US4749780A (fr)
EP (1) EP0197901B1 (fr)
JP (1) JPS61205219A (fr)
AT (1) ATE65505T1 (fr)
CA (1) CA1341497C (fr)
DE (1) DE3680368D1 (fr)
DK (1) DK164282B (fr)
HK (1) HK15293A (fr)
SE (1) SE8501050D0 (fr)
SG (1) SG1893G (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
JP2593500B2 (ja) * 1986-06-24 1997-03-26 ノルデイスク ゲントフテ エー／エス ▲ｖｉｉｉ▼因子フラグメントの凝固活性複合物の製造方法
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
ATE168059T1 (de) * 1992-04-06 1998-07-15 Pressmaster Tool Ab Crimp-werkzeug
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP0910581B1 (fr) * 1996-06-24 2000-04-05 Max-Planck-Institut für Physiologische und Klinische Forschung Kerckhoff-Klink GmbH Procede pour la purification par chromatographie d'affinite du facteur viii
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) * 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
EP1038959A1 (fr) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Facteur VIII sans domaine B, comprenant une ou plusieurs insertions d'intron I tronqué du facteur IX
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP1233064A1 (fr) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung ADNc modifier du facteur VIII et son d'utilisation pour la production du facteur VIII
EP1421539B1 (fr) 2001-06-14 2009-10-28 The Scripps Research Institute Facteur viii stabilise avec des liaisons disulfure genetiquement modifiees
EP1418810A4 (fr) 2001-08-03 2006-08-02 Us Gov Health & Human Serv Traitement de l'hemophilie par voie orale
SI2574677T1 (sl) 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
EP2704688B1 (fr) * 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Compositions de cochléate et leurs procédés de fabrication et d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
US4650858A (en) * 1983-03-21 1987-03-17 Nordisk Gentofte A/S Concentrate of the antihemophilic factor VIII and a process for producing it
IE80858B1 (en) * 1983-03-31 1999-04-21 Scripps Research Inst New factor viii coagulant polypeptides
DE10399009I1 (de) * 1984-01-12 2003-10-23 Chiron Corp F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof

Also Published As

Publication number Publication date
DE3680368D1 (de) 1991-08-29
JPS61205219A (ja) 1986-09-11
EP0197901B1 (fr) 1991-07-24
US4749780A (en) 1988-06-07
EP0197901A1 (fr) 1986-10-15
SE8501050D0 (sv) 1985-03-05
DK164282B (da) 1992-06-01
JPH0547524B2 (fr) 1993-07-19
US4877614A (en) 1989-10-31
DK85786A (da) 1986-09-06
DK85786D0 (da) 1986-02-25
HK15293A (en) 1993-03-05
ATE65505T1 (de) 1991-08-15
CA1341497C (fr) 2006-02-14

Similar Documents

Publication Publication Date Title
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
GEP20084347B (en) New derivatives of diphosphonic acid, method for their preparation and medicamentous form containing them
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
IL74804A0 (en) Human physiologically active polypeptide,its production and pharmaceutical compositions containing it
EP0149468A3 (en) Biologically active substance with hormonal characteristics, process for its preparation and use of histons for medicinal ends
EP0151989A3 (en) Means for the treatment of cardiac diseases
IL81573A (en) Pharmaceutical preparations for the treatment of psoriasis containing tamoxifen
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
EP0177342A3 (fr) Formulations orales de protéines thérapeutiques
AU564439B2 (en) Pharmaceutical compositions containing l-alpha- glycerylphosphorylcholine
GR3019171T3 (en) System for delivering drug with enhanced bioacceptability.
HU907959D0 (en) Medical preparations
DE69431046D1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
HU902004D0 (en) New trombolitic preparations
MY104942A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2-ones.
BG44709A3 (bg) Метод за получаване на 9-хлор-1,5-бензотиазепинови производни
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
EP0180737A3 (en) Use of preparations containing gamma-interferon (ifn-gamma) for treating rheumatic diseases
ES8603270A1 (es) Procedimiento para preparar liposomas que contiene alergenoso fracciones de alergenos inhalables
HU896052D0 (en) Process for the preparation of peptides with t-cell suppressoral activity and medical preparations containing such peptides
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
EP0343671A3 (en) Pharmaceutical composition for the treatment of skin wounds
ZA885625B (en) Therapeutic agents containing enantiomers of propafenone
ZA868813B (en) Dna sequence,recombinant dna and process for producing human tissue plasminogen activator